Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin

References

• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713–19
   PubMed Web of Science ®Google Scholar
• Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611–14
   PubMed Web of Science ®Google Scholar
• American DA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36 Suppl 1:S67–74
   Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162–72
   PubMed Web of Science ®Google Scholar
• Pratley RE. The early treatment of type 2 diabetes. Am J Med 2013;126:S2–9
   Google Scholar
• Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs 2013;73:327–39
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77–82
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1–45
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574–9
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
   PubMed Web of Science ®Google Scholar
• Panagoulias GS, Doupis J. Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Prefer Adherence 2014;8:227–36
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Diabetes Treatment, Part 2: oral agents for glycemic management. Clin Diabetes 2007;25:131–4
   Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16:195–202
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527–39
   PubMed Web of Science ®Google Scholar
• Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565–72
   PubMed Web of Science ®Google Scholar
• Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141–60
   PubMed Web of Science ®Google Scholar
• Magni P, Macchi C, Morlotti B, et al. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med 2015;26:82–8
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96
   PubMed Web of Science ®Google Scholar
• Kandhwal K, Dey S, Nazarudheen S, et al. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study. Clin Drug Investig 2011;31:853–63
   PubMed Web of Science ®Google Scholar
• Matafome P, Louro T, Rodrigues L, et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011;27:54–62
   PubMed Web of Science ®Google Scholar
• Kim BH, Han S, Lee H, et al. Metformin enhances the anti-adipogenic effects of atorvastatin via modulation of STAT3 and TGF-β/Smad3 signaling. Biochem Biophys Res Commun 2015;456:173–8
   PubMedGoogle Scholar
• Boldhane SP, Kuchekar BS. Gastroretentive drug delivery of metformin hydrochloride: formulation and in vitro evaluation using 3(2) full factorial design. Curr Drug Deliv 2009;6:477–85
   PubMedGoogle Scholar
• Sugihara H, Matsui Y, Takeuchi H, et al. Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies. Eur J Pharm Sci 2014;53:62–8
   PubMed Web of Science ®Google Scholar
• Shah RP, Kumar V, Singh S. Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun Mass Spectrom 2008;22:613–22
   PubMed Web of Science ®Google Scholar
• Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison – statistics and analysis of the similarity factor, f2. Pharm Res 1998;15:889–96
   PubMed Web of Science ®Google Scholar
• Midha KK, McKay G. Bioequivalence; its history, practice, and future. Aaps J 2009;11:664–70
   PubMed Web of Science ®Google Scholar
• Ferrero C, Bravo I, Jimenez-Castellanos MR. Drug release kinetics and fronts movement studies from methyl methacrylate (MMA) copolymer matrix tablets: effect of copolymer type and matrix porosity. J Control Release 2003;92:69–82
   PubMed Web of Science ®Google Scholar
• Yassin S, Su K, Lin H, et al. Diffusion and swelling measurements in pharmaceutical powder compacts using terahertz pulsed imaging. J Pharm Sci 2015;104:1658–67
   PubMed Web of Science ®Google Scholar
• Corti G, Cirri M, Maestrelli F, et al. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin. Eur J Pharm Biopharm 2008;68:303–9
   PubMed Web of Science ®Google Scholar
• Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 2000;50:325–32
   PubMed Web of Science ®Google Scholar
• Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res 1997;14:815–19
   PubMed Web of Science ®Google Scholar
• Waterman KC. A critical review of gastric retentive controlled drug delivery. Pharm Dev Technol 2007;12:1–10
   PubMed Web of Science ®Google Scholar
• Basak SC, Rahman J, Ramalingam M. Design and in vitro testing of a floatable gastroretentive tablet of metformin hydrochloride. Pharmazie 2007;62:145–8
   PubMed Web of Science ®Google Scholar
• Yadav A, Jain DK. Gastroretentive microballoons of metformin: Formulation development and characterization. J Adv Pharm Technol Res 2011;2:51–5
   PubMedGoogle Scholar
• Oh TO, Kim JY, Ha JM, et al. Preparation of highly porous gastroretentive metformin tablets using a sublimation method. Eur J Pharm Biopharm 2013;83:460–7
   PubMed Web of Science ®Google Scholar
• Kuan G. Analytes of interest and choice of dose: two important considerations in the design of bioequivalence studies with atorvastatin. J Bioequiv Bioavailab 2011;3:63–8
   Google Scholar